Proactive Investors - Run By Investors For Investors

Midatech Pharma PLC - Addressing high unmet need in cancer markets

A fully integrated specialty pharma company, Midatech Pharma (LON:MTPH) is rapidly progressing the development of three lead R&D programs. They have developed three proprietary drug delivery technologies (Q-Sphera, Gold Nano Particle and Nano Inclusion) to improve and expand the therapeutic potential of validated drug products. At the same time Midatech has built a US commercial unit focused on supportive care products.
Midatech Pharma PLC - Addressing high unmet need in cancer markets

Following a c. £6mln rights issue in October 2017 and a £15mln loan agreement finalised in January 2018, Midatech looks fully funded until year-end.
Stock price at multi-year lows, yet potential to address high unmet need in large cancer markets in the near term, suggests an attractive entry point.

Full report is available via Capital Network website
View full MTPH profile View Profile

Midatech Pharma Plc Timeline

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use